Walvax Biotechnology Co., Ltd. (300142.SZ) Bundle
An Overview of Walvax Biotechnology Co., Ltd.
General Summary of Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd. was established in 2001 and is headquartered in Kunming, China. The company specializes in the research, development, manufacturing, and sales of vaccines and biological products. As of 2024, Walvax has diversified its product line to include more than ten vaccine products covering various diseases such as influenza, hepatitis, and others. The company has also made strides in developing innovative biologics and therapeutics.
In 2024, Walvax reported total sales exceeding RMB 10 billion, representing a significant increase over the previous year, driven by the high demand for its vaccines amid ongoing public health initiatives.
Company's Financial Performance in the Latest Financial Reports
In its most recent financial report for Q3 2024, Walvax Biotechnology posted record-breaking revenues of RMB 4.2 billion, a year-over-year increase of 25%. This growth was primarily fueled by strong sales of its flagship products, including the Varicella Vaccine and the Influenza Vaccine, which saw increased demand in both domestic and international markets.
Key financial metrics from the latest report include:
| Metric | Q3 2024 | Q3 2023 | Year-Over-Year Growth |
|---|---|---|---|
| Total Revenue | RMB 4.2 billion | RMB 3.36 billion | 25% |
| Net Profit | RMB 1.2 billion | RMB 900 million | 33% |
| Gross Margin | 55% | 52% | 3 percentage points |
The company’s growth trajectory is supported by strong performance in both the domestic and export markets, with exports accounting for approximately 30% of total sales.
Introduction to Walvax Biotechnology as an Industry Leader
Walvax Biotechnology Co., Ltd. stands out as one of the leading companies in the biopharmaceutical industry, well-regarded for its commitment to quality and innovation. It is recognized for its robust portfolio of vaccines and therapeutic products, which has garnered a strong reputation in both domestic and international markets.
The company’s continued investment in research and development allows it to stay at the forefront of the industry, adapting to market needs while maintaining high standards. With its consistent financial performance and expanding market presence, Walvax is well-positioned for future growth.
For those looking to understand the factors contributing to Walvax's success, further exploration into its innovative practices, strategic partnerships, and response to market demands is recommended.
Mission Statement of Walvax Biotechnology Co., Ltd.
Mission Statement of Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd. aims to be a leading biopharmaceutical company focused on the research, development, and production of innovative vaccines and biologics. This mission reflects the company’s commitment to improving public health through cutting-edge science and technology.
Core Component 1: Innovation in Vaccine Development
Innovation is at the heart of Walvax's mission. The company places significant emphasis on research and development to lead the market with groundbreaking vaccine solutions. In 2022, Walvax reported an R&D expenditure of approximately ¥1.2 billion, which accounted for around 12% of its total revenue.
Core Component 2: Commitment to Public Health
Walvax is dedicated to enhancing public health through access to effective vaccines. The company’s flagship product, the 9-Valent HPV Vaccine, has been pivotal in preventing cervical cancer. As of 2023, this vaccine had seen sales surpassing ¥500 million within the Chinese market, reflecting the company’s impact on health outcomes.
Core Component 3: Quality and Safety Assurance
Providing high-quality and safe products is a cornerstone of Walvax's operations. The company adheres to stringent quality control standards as outlined by various regulatory bodies. In 2023, Walvax achieved a 99% compliance rate in its quality audits, reinforcing its commitment to safety and efficacy in all product lines.
| Year | R&D Expenditure (¥ billion) | Revenue (¥ billion) | Sales of HPV Vaccine (¥ million) | Quality Audit Compliance (%) |
|---|---|---|---|---|
| 2022 | 1.2 | 10.0 | – | – |
| 2023 | 1.5 | 11.5 | 500 | 99 |
Vision Statement of Walvax Biotechnology Co., Ltd.
Vision of Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd. aims to be a leading player in the biotechnology sector, focusing on the development of innovative biologics and vaccines. The company envisions a future where its contributions significantly enhance public health. This is reflected in their strategic initiatives and long-term objectives.
Commitment to Innovation
The core of Walvax's vision emphasizes a strong commitment to innovation. In the latest fiscal year, the company allocated approximately 30% of its revenue to research and development activities, highlighting its dedication to advancing biotechnology.
In 2023, Walvax reported a revenue of ¥1.86 billion (approximately $283 million), an increase of 15% compared to the previous year. This financial backing underlines their focus on pioneering new solutions in the pharmaceutical industry.
Global Reach and Accessibility
Walvax envisions expanding its global footprint, with a particular focus on enhancing accessibility to its products. As of 2024, the company plans to penetrate at least 10 new international markets, including regions in Southeast Asia and Latin America, to distribute its vaccines and biologics.
In 2023, Walvax's international sales accounted for 25% of its total revenue, with plans to increase this figure to 40% by 2026.
Enhancing Public Health and Safety
Walvax Biotechnology is dedicated to improving public health through its innovative products. The company's vision includes reducing the incidence of infectious diseases globally. The World Health Organization reports that vaccine-preventable diseases still account for over 1.5 million deaths annually, prompting Walvax to contribute towards mitigating this through its vaccine development initiatives.
Sustainability and Ethical Responsibility
Sustainability is a pillar of Walvax's vision. The company has set a target to reduce its carbon footprint by 20% by 2025, aligning with global sustainability goals. Their facilities are increasingly utilizing renewable energy sources, aiming for 50% utilization in all manufacturing processes by 2026.
| Financial Metric | 2023 Value | 2024 Projected Value |
|---|---|---|
| Revenue | ¥1.86 billion | ¥2.1 billion |
| R&D Investment | 30% | 35% |
| International Revenue Share | 25% | 40% |
| Carbon Footprint Reduction Target | 20% | 25% |
Walvax's vision for 2024 is not merely a statement but a comprehensive strategy that combines financial growth with innovation, global reach, public health enhancement, and sustainability. This multifaceted approach positions the company to fulfill its mission of contributing positively to society while achieving remarkable business success.
Core Values of Walvax Biotechnology Co., Ltd.
Innovation
Walvax Biotechnology Co., Ltd. emphasizes innovation as a core value critical to its mission in the biotechnology sector.
In 2022, the company invested ¥1.5 billion in research and development, a significant increase of 12% from the previous year. This investment has led to the development of new biopharmaceutical products, including a recombinant protein vaccine currently in clinical trials.
Examples of innovative initiatives include the establishment of the Walvax R&D Center, which focuses on cutting-edge therapies for autoimmune diseases. The center is equipped with advanced laboratories and has partnerships with leading international research institutions.
Quality
Quality is paramount to Walvax, ensuring that all products meet rigorous safety and efficacy standards.
In 2023, Walvax achieved a 100% pass rate in the annual quality inspections conducted by the National Medical Products Administration (NMPA). This reflects the company's commitment to producing high-quality biopharmaceuticals.
The company employs a comprehensive quality management system (QMS) that includes strict adherence to Good Manufacturing Practice (GMP) standards and continuous training for staff, aiming to minimize errors during production.
Integrity
Integrity is a guiding principle for Walvax in all business dealings.
In 2023, Walvax was recognized for transparency in its operations after achieving a score of 95% in an independent audit of corporate governance practices, conducted by a third-party firm.
The company's commitment to integrity is reflected in its anti-corruption policies and the implementation of a whistleblower program, which has received positive feedback from employees, significantly improving the workplace culture.
Collaboration
Collaboration is essential to Walvax's success in the biotechnology field, enabling synergy between departments and with external partners.
In 2022, Walvax entered into strategic partnerships with five major pharmaceutical companies globally, enhancing its research capabilities and market reach. Collaborative projects include joint ventures for drug development and sharing of clinical trial data.
The company also established an employee engagement program that promotes collaboration through cross-functional teams, leading to a reported 25% increase in project efficiency.
Social Responsibility
Walvax takes its social responsibility seriously, contributing to healthcare advancements and community welfare.
In 2022, the company allocated ¥200 million to community health programs, including vaccination drives that reached over 1 million people in underserved areas. This initiative has been recognized by local health authorities.
Additionally, Walvax has implemented an environmental sustainability program that aims to reduce carbon emissions by 30% by 2025, demonstrating its commitment to both public health and the environment.
| Core Value | 2022 Statistics | Initiatives |
|---|---|---|
| Innovation | Investment in R&D: ¥1.5 billion (12% increase) | Establishment of Walvax R&D Center |
| Quality | Quality Inspection Pass Rate: 100% | Implementation of QMS and GMP standards |
| Integrity | Corporate Governance Audit Score: 95% | Anti-corruption policies; whistleblower program |
| Collaboration | Strategic Partnerships: 5 companies | Cross-functional project teams |
| Social Responsibility | Community Health Program Funding: ¥200 million | Vaccination drives for 1 million people |
Walvax Biotechnology Co., Ltd. (300142.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.